Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
When autistic kids grow up, Chapter 4: How did things unfold?
Tempest McDonald sues Vanderbilt University Medical Center through the Equal Employment Opportunity Commission. Her published NIH paper finds allies.
When autistic kids grow up, Chapter 4: How did things unfold?
Tempest McDonald sues Vanderbilt University Medical Center through the Equal Employment Opportunity Commission. Her published NIH paper finds allies.
NeuroDev study maps previously unseen genetic variation in Africa
The project is helping to fill critical gaps in the genetic underpinnings of autism and other neurodevelopmental conditions.
NeuroDev study maps previously unseen genetic variation in Africa
The project is helping to fill critical gaps in the genetic underpinnings of autism and other neurodevelopmental conditions.
Cooperating marmosets extend decision-making model of the brain
When a pair of marmosets works together to earn some marshmallow fluff, one of them decides to act only after its brain accumulates enough evidence about what the other is doing, new work shows.
Cooperating marmosets extend decision-making model of the brain
When a pair of marmosets works together to earn some marshmallow fluff, one of them decides to act only after its brain accumulates enough evidence about what the other is doing, new work shows.